AOA Dx
Blood Test for Early Detection of Ovarian Cancer
AI‑enabled platform for early cancer detection focused on women’s health.
- Founders
- Oriana Papin-Zoghbi, Alex Fisher, Anna Jeter
- YC batch
- S21
Company posts
Summaries from the company’s own website.
- AOA Dx Publishes Peer-Reviewed Study Validating the Biology Behind Its Multi-Omic Approach to Earlier Ovarian Cancer Detection ↗
AOA Dx says it published a peer-reviewed study in Diagnostics on multi-omic profiling of ovarian cancer serum from a symptomatic cohort. The company says the findings support the biological basis of its AKRIVIS GD test and GlycoLocate platform and suggest that combining lipids, metabolites, and proteins reveals signals not seen in single-omics tests.
- AOA Dx Pioneers Translation of Lipid Biomarkers into a Targeted Multi-omic Assay, Achieving 92% Early-Stage Ovarian Cancer Sensitivity in Symptomatic Women ↗
AOA Dx said it presented new ASCO data showing its AKRIVIS GD multi-omic blood test detected early-stage ovarian cancer with 92% sensitivity in symptomatic women. The company said the results support its approach of combining lipid, protein, and metabolite biomarkers with machine learning and moving the assay toward early access launch.